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Dr John Blebea (Philadelphia, Pa). There appears to be a big
discrepancy between the outcome with subintimal angioplasty
versus standard transluminal angioplasty in terms of patency rates.
There is also a major decreased patency among those vessels with
low flow rate. Were the overall flow rates within the popliteal artery
less for the patients undergoing subintimal angioplasty as a group,
not just the proportion that thrombosed or had low flows later?
Dr Anil P. Hingorani. No, they weren’t. They were actually
pretty similar when we looked at the popliteal artery volume flows
at the end of the procedure. We were not able to differentiate
between these two groups.
Dr Jacob Schneiderman (Tel-Hashomer, Israel). How do
you verify that there were no distal emboli related to the proce-
dure? Are you doing any completion evaluation of the distal tree?
Dr Hingorani. As we mentioned before, with the duplex
imaging, before the procedure we look at the tibial vessels, and
after the procedure we also look at the tibial vessels. With duplex
imaging, you can actually see all the way down to the pedal vessels.
Dr Schneiderman. So you feel confident with this ultrasound
evaluation to conclude that no emboli went to the distal tree?
Dr Hingorani. We’ve already had over a thousand patients
that we’ve evaluated preoperatively for open procedures, not only
including the femoropopliteal segment but all the way down to the
tibials and the pedal vessels, and done bypasses based upon those.
However, the limitations are actually, I think, the key. You
don’t want to be doing these patients who have very calcified
vessels where you can’t see what’s going on very well. You don’t
want to be doing this in patients who have a tremendous amount of
tissue edema because you’re not going to be able to evaluate the
vessels well. You don’t want to be doing this in patients whose SFA
is 6 cm deep, you’re not going to be able to visualize and get
enough information to do these types of procedures.
Dr Hasan Dosluoglu (Buffalo, NY). I have two quick ques-
tions. You have studied a good number of stented patients, so
could you identify those who had developed more restenosis,
depending on the flow patterns. If you end up with a patient who
has suboptimal flow, and you cannot identify why that is, what do
you do with these patients?
Dr Hingorani. That second question is actually, I think, one
of the more important points. Those types of patients we persis-
tently try to look for an inflow lesion or an outflow lesion. Maybe
we missed something on the inflow and we’ll go back up and look
at the iliac arteries to make sure we didn’t miss anything. Unfor-
tunately, we haven’t very often found an inflow or an outflow
problem. And when you don’t, I usually don’t reverse the heparin
and don’t administer the protamine in these types of patients.
In general, we thought we were actually doing okay, because
in the recovery room they seemed to be doing all right. But,seemed to do much, much worse. They had much higher rates of
early thrombosis despite our maneuvers of not reversing the hep-
arin.
We were not actually able to differentiate which patients, even
with or without stenting, would have long-term patency based on
this data set.
Dr Rumi Faizer (Columbia, Mo). A few questions. First, you
must have a good reason why you’re using flow volume and not
peak velocities and waveforms. And I was wondering how you
came to that determination?
Second question. Many of us have been impressed with how
you can see a pressure gradient down the SFA and not a clear
stenosis on imaging with angio. And I thought that’s a wonderful
place for this to show itself. I was wondering if you had any
correlation between intravascular pressure gradients versus wave-
forms that you’re seeing?
And then, lastly, I was a little bit confused with how you had
such a high proportion of TASC C and D lesions, and yet the ABI
is averaging 0.68. Why such a discrepancy? I would have expected
lower ABIs in this population.
Dr Hingorani. Initially, when you want to try to start doing
these types of protocols, you don’t want to be doing the TASC Cs
and Ds. You want to start off with the thin patient, whose vessels
you can easily see, with a short focal stenosis. When you want to
start off doing these, we actually suggest that you start doing it
preoperatively and not in the operating room, and compare it to
angiography for at least the first 25, until you’re certain that your
results that you’re getting from the technologist are greater than
95% accuracy.
We have not compared pressure gradients to these patients.
But I think you’re actually bringing up one of the clear advantages
that other people have already shown in data sets, that duplex
imaging, if you take your patient that you did an SFA angioplasty
and you immediately do a duplex, you’ll find a fair number of
lesions that youmissed on angiography, even with biplanar angiog-
raphy, unfortunately. So I think that actually may contribute to
one of the reasons why we are stenting a lot more patients as
compared to our angiogram patients, because I think we are seeing
a lot more lesions that may have been missed. We are seeing a lot
more recoil. We are seeing a lot more dissection.We are seeing a lot
more residual stenoses that I think we are missing on angiography.
But we don’t have data comparing it to pressure gradients.
We do use peak systolic velocities routinely. We do use mode
B imaging before, after, and during the procedures. This data set
right now is just mostly looking at the next step, looking at
popliteal artery volume flows.
The average ABIs, I wouldn’t be able to say. That’s what the
numbers were, 0.68. 68% of our patients were claudicants, so I
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Dr Charles Brantigan (Denver, Colo). Let me change the
focus of the discussion for a moment from the technical to the
physiologic. The last statement in your conclusions in the abstract
says that “Perhaps pharmacological manipulation in this high-risk
group of patients may enhance patency rates.” I am assuming you
are talking about vasodilator therapy of some type. What therapy
are you proposing, and for how long are you proposing to use it to
enhance the patency rates?
Dr Hingorani. Unfortunately, as you know, the vasodilators
have really not really been that helpful. And right now, as I said, all
we are doing right now is not reversing the heparin. All of thesethe procedures. And actually, we are leaving them on Plavix for at
least 3 to 6 months after these procedures, irrespective of the
popliteal artery volume flows. If we encounter a low popliteal
volume flow, we’re routinely not reversing heparin, but we are not
using any dilators or such.
Dr Brantigan. So you are not actually proposing any different
pharmacologic management for the two groups of patients?
Dr Hingorani. Not yet.
Dr Brantigan. Except, perhaps, not reversing the heparin,
which many people wouldn’t do anyway.
Dr Hingorani. Not yet. I don’t think we really have that
many alternatives as of yet. That would be a point of discussion and
patients are on Plavix preoperatively and on indefinite aspirin after a possible route of further investigation.
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